Please assess the completion status of the following clinical trial:

Trial Title: Daptomycin for the Treatment of Infections Due to Gram-Positive Bacteria

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Main Inclusion Criteria:~* Infection caused by Staphylococcus aureus, Staphylococcus epidermidis, Enterococcus faecalis, or Enterococcus faecium that requires inpatient hospitalization and treatment with injectable antibiotics\*\*~* Site of infection: complicated skin and skin structure infection; urinary tract infection; intra-abdominal infection; infective endocarditis; or bloodstream infection (including catheter-related).~* Pathogen resistant to, or patient intolerant of: beta-lactams, vancomycin, quinupristin/dalfopristin, or linezolid.~* Unable to receive any other standard commercially available antibacterial therapy for the infection.~Main Exclusion Criteria:~* Creatinine clearance less than 40 mL/min\*\*~* Hemodialysis or peritoneal dialysis~* Admitted to the hospital for drug overdose or other conditions associated with rhabdomyolysis, or is expected to require repeated intramuscular injections~* Creatine phosphokinase (CPK) level greater than 2.5 times above the upper limit of normal (ULN) at screening; if the elevation in CPK can be attributed to an obvious cause (eg, surgery)\*\*~* Central nervous system infection~* Pulmonary infection.~(\*\*) An exemption may be granted for patients not satisfying these criteria following a conversation with the Medical Monitor.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).